Non Small Cell Lung Cancer Clinical Trials in Tampa, Florida

22 studies are recruiting for non small cell lung cancer in Tampa, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

   This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical ([225Ac]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administe…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   14 in total

   Run by

   Aktis Oncology, Inc.

   See if you can join NCT07020117 on ClinicalTrials.gov

2. Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

   To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1, or HER2-genomically altered lung cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT05681780 on ClinicalTrials.gov

3. A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

   Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib compared to …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Moffitt Cancer Center /ID# 276785, Tampa, Florida

   Locations

   116 in total

   Run by

   AbbVie

   See if you can join NCT07155187 on ClinicalTrials.gov

4. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

   This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   38 in total

   Run by

   Genentech, Inc.

   See if you can join NCT04302025 on ClinicalTrials.gov

5. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

   This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   H. Lee Moffit Cancer center and research institute, Tampa, Florida

   Locations

   262 in total

   Run by

   BioNTech SE

   See if you can join NCT06712316 on ClinicalTrials.gov

6. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

   Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   16 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT04981119 on ClinicalTrials.gov

7. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

   Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Tampa, Florida

   Locations

   23 in total

   Run by

   AstraZeneca

   See if you can join NCT05877599 on ClinicalTrials.gov

8. Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

   This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   8 in total

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT06745882 on ClinicalTrials.gov

9. Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

   Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (N…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

   Locations

   158 in total

   Run by

   Nuvalent Inc.

   See if you can join NCT06765109 on ClinicalTrials.gov

10. A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

    A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    3 in total

    Run by

    Blueprint Medicines Corporation

    See if you can join NCT07629960 on ClinicalTrials.gov

11. A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

    The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that int…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Moffitt Cancer Center ( Site 0078), Tampa, Florida

    Locations

    229 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06077760 on ClinicalTrials.gov

12. Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

    The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved, on-label systemic therapy utilizing immune checkpoint inhib…

    Stage

    Phase 3

    Ages

    18 to 100

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    14 in total

    Run by

    InSightec

    See if you can join NCT05317858 on ClinicalTrials.gov

13. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Florida Cancer Specialists, Tampa, Florida

    Locations

    440 in total

    Run by

    Pfizer

    See if you can join NCT07222566 on ClinicalTrials.gov

14. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well as treatment-naïve, advanced/metastatic non-small cell lung cancer (NSC…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffit Cancer Center, Tampa, Florida

    Locations

    85 in total

    Run by

    BioNTech SE

    See if you can join NCT07111520 on ClinicalTrials.gov

15. IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

    In Cohort 1, the study was intended to assess safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab, in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung c…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

    Locations

    30 in total

    Run by

    Innate Pharma

    See if you can join NCT05742607 on ClinicalTrials.gov

16. A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

    The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesotheli…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    12 in total

    Run by

    A2 Biotherapeutics Inc.

    See if you can join NCT06051695 on ClinicalTrials.gov

17. MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

    This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary efficacy of MEM-288 in patients with advanced solid tumors. Eligible sub…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    2 in total

    Run by

    Memgen, Inc.

    See if you can join NCT05076760 on ClinicalTrials.gov

18. BBO-11818 in Adult Subjects With KRAS Mutant Cancer

    A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    17 in total

    Run by

    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

    See if you can join NCT06917079 on ClinicalTrials.gov

19. A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

    The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    9 in total

    Run by

    Teligene US

    See if you can join NCT06010329 on ClinicalTrials.gov

20. Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

    This is a Phase II, multisite, open-label study consisting of two parts in participants with advanced/metastatic Non-small Cell Lung Cancer (NSCLC) which progressed after a first-line chemoimmunotherapy to evaluate the combination of pumitamig (also known as BNT327, BMS-986545 or PM8002) with stand…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    30 in total

    Run by

    BioNTech SE

    See if you can join NCT06841055 on ClinicalTrials.gov

21. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage

    Not phased

    Ages

    Any age

    Site

    Massive Bio SYNERGY-AI site, Tampa, Florida

    Locations

    68 in total

    Run by

    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

22. Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

    This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned;…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    6 in total

    Run by

    Simcha IL-18, Inc.

    See if you can join NCT04787042 on ClinicalTrials.gov